Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature.
OBJECTIVE
Sex cord-stromal tumours of the testis are uncommon tumours, accounting for around 5% of testicular neoplasms. Treatment is primarily surgical, with no adjuvant therapy of proven benefit. We present a single-centre experience over a period of 15 years.


METHODS
From 1988 to 2002, 18 patients with a diagnosis of sex cord-stromal tumour were referred to our centre. A retrospective analysis of their case notes was made and a pathological review undertaken.


RESULTS
Sixteen were Leydig-cell tumours and two were Sertoli cell. For the Leydig-cell tumours, the median age at presentation was 42 years, 50% presented with a testicular mass and 31% with gynaecomastia. Two patients followed a malignant course: one revealing disease dissemination at initial staging, and a second 12 months after potentially curative orchidectomy. Salvage retroperitoneal lymphadenectomy in the latter patient proved unsuccessful. Clinical outcome correlated strongly with the presence of adverse pathological features described previously in the literature. After a median follow-up of 46 months, two patients have developed progressive disease, and two patients have died, one of metastatic Leydig-cell tumour. No patient defined as being of low malignant potential on pathological examination has relapsed outside our review period of 2 years.


CONCLUSIONS
We confirm the overall excellent prognosis for most of the patients with sex cord-stromal tumours of the testis. Compared with most previous reports, pathological features seem to predict with reasonable accuracy the risk of malignant behaviour, and can adequately inform the subsequent review policy.
Conkey
D S
DS
Urological Oncology Section, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
Howard
G C W
GC
Grigor
K M
KM
McLaren
D B
DB
Kerr
G R
GR
D000328:Adult; D000368:Aged; D006801:Humans; D008297:Male; D011379:Prognosis; D012187:Retroperitoneal Space; D012189:Retrospective Studies; D012606:Scotland; D012707:Sertoli Cell Tumor / Q000473:pathology; D018310:Sertoli-Leydig Cell Tumor / Q000473:pathology; D018312:Sex Cord-Gonadal Stromal Tumors / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D013736:Testicular Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome